Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting
October 05, 2022 08:10 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 10, 2022 07:00 ET
|
Tango Therapeutics, Inc.
– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor – – Received Orphan Drug Designation in US for the treatment...
Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
August 02, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
June 27, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 11, 2022 07:00 ET
|
Tango Therapeutics, Inc.
– Phase 1/2 trial of TNG908, a synthetic lethal PRMT5 inhibitor, for the treatment of MTAP-deleted solid tumors open for enrollment – – Declared TNG462 as a development candidate - a...
Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022
May 09, 2022 07:00 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 28, 2022 07:00 ET
|
Tango Therapeutics, Inc.
- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 - - Pipeline programs progressing throughout 2022 - - Strong cash position of $485 million expected to...
Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting
March 08, 2022 16:57 ET
|
Tango Therapeutics, Inc.
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer...